Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	32.4B	31.6B	28.0B	22.8B	21.3B
Cost of Revenue	4.7B	4.4B	3.8B	3.5B	3.5B
Gross Profit	27.8B	27.3B	24.1B	19.3B	17.8B
Operating Expenses
R&D Expense	7.4B	7.0B	6.6B	5.0B	4.9B
SG&A Expense	3.1B	—	—	—	—
General & Admin Expense	2.1B	2.8B	2.6B	2.4B	2.3B
Selling & Marketing Expense	6.9B	9.1B	8.3B	7.6B	7.3B
Other Expenses	92.5M	—	—	—	—
Total Operating Expenses	19.7B	18.7B	17.2B	14.7B	14.3B
Cost and Expenses	24.4B	23.1B	21.0B	18.2B	17.7B
Operating Income (EBIT)	8.3B	9.0B	7.5B	4.9B	4.1B
Non-Operating
Interest Income	449.6M	—	—	—	—
Interest Expense	2.9M	—	—	—	—
Net Interest Income	446.6M	—	—	—	—
Other Non-Op Income/Expense	918.5M	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	9.0B	8.7B	7.2B	4.7B	4.0B
Income Tax Expense	913.4M	990.6M	832.7M	389.3M	153.4M
Bottom Line
Net Income	8.1B	7.7B	6.3B	4.3B	3.9B
Earnings from Cont. Ops	8.1B	7.7B	6.3B	4.3B	3.8B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	8.1B	7.7B	6.3B	4.3B	3.9B
Per Share
Basic EPS	CN¥1.22	CN¥1.19	CN¥1.00	CN¥0.68	CN¥0.61
Diluted EPS	CN¥1.22	CN¥1.18	CN¥1.00	CN¥0.68	CN¥0.61
Revenue Per Share	CN¥4.91	CN¥4.88	CN¥4.42	CN¥3.61	CN¥3.32
Shares
Basic Shares Outstanding	6.6B	6.5B	6.3B	6.3B	6.4B
Diluted Shares Outstanding	6.6B	6.5B	6.3B	6.3B	6.4B
Profitability Metrics
EBITDA	2.1B	9.9B	8.3B	5.7B	4.7B
D&A	308.2M	901.5M	817.1M	755.8M	605.4M
EBIT	1.8B	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026